The Presidential Task Force on COVID-19 has said the Federal Ministry of Health has shortlisted for further investigations, three Nigerian drugs, which have the potential to cure COVID-19 or treat its symptoms.
The Chairman of the Presidential Task Force on COVID-19 and Secretary to the Government of the Federation, Mr Boss Mustapha, disclosed this on Wednesday at the PTF press conference in Abuja, where the ministry of health warned that Nigeria’s health system could not cope with increasing COVID-19 cases.I
But Mustapha said three shortlisted drugs would be subjected to further investigations by relevant health agencies.
The Minister of State for Health, Senator Olorunnimbe Mamora, who confirmed the screening to The PUNCH, said the companies had been asked to submit samples of their drugs.
At the PTF press briefing on Wednesday, Mustapha disclosed that the Federal Ministry of Health had held a virtual meeting with some researchers and scientists who had made claims about COVID-19 cure and shortlisted three for further research.
He stated, “As a measure of the importance attached to research and development of local capacity for finding a cure to the COVID-19, the Federal Ministry of Health held a virtual meeting with a number of researchers and scientists with claims to cure for COVID 19 and out of the numerous claimants, three were found to deserve further investigation and have been forwarded to the relevant authorities for appropriate review.
“Similarly, efforts are being made by the Federal Ministry of Science and Technology to subject some locally manufactured COVID-19 equipment to verification and subsequent certification.”
The task force also backed the decision of the World Health Organisation to suspend clinical trials of hydroxychloroquine for the treatment of the novel coronavirus.
The PTF Chairman, Mustapha, therefore cautioned the National Agency for Food and Drug Administration and Control and other relevant agencies to ensure that all claims to treatment by scientists and researchers were subjected to scientific certification protocols.
The WHO had on Monday suspended the hydroxychloroquine trials because of the high mortalities among patients the drug was administered on.
On Tuesday, NAFDAC Director General, Prof Mojisola Adeyeye, said the agency would go ahead with the trial on the grounds that it had been effective in the treatment of COVID- 19 patients, especially those at the mild stage of the virus.
The Punch
